A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
Cancer Breast Cancer Breast Cancer Er-Positive Breast Cancer HER-2 Negative
For the latest version of this information please go to www.forpatients.roche.com